Company Overview of Taisho Pharmaceutical Co., Ltd.
Taisho Pharmaceutical Co., Ltd. develops, manufactures, and sells over-the counter medications, prescription pharmaceuticals, and health-care-related products. The company offers its products in the areas of CNS, diabetes, immunology/allergy, and infectious diseases. It also provides health information through community pharmacies and drugstores. It sells its products through its subsidiaries in Hong Kong, Taiwan, Malaysia, the Philippines, Indonesia, Thailand, Vietnam, China, Australia, the United States, and the United Kingdom. The company was founded in 2011 and is based in Tokyo, Japan. Taisho Pharmaceutical Co., Ltd. operates as a subsidiary of Taisho Pharmaceutical Holdings Co., Ltd.
Founded in 2011
Key Executives for Taisho Pharmaceutical Co., Ltd.
Executive Vice President and Director
Managing Director and Director
Managing Director and Director
Compensation as of Fiscal Year 2014.
Taisho Pharmaceutical Co., Ltd. Key Developments
Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd. Announce Positive Results from Phase III Osteoporosis Trial
Apr 9 15
Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd., have announced positive results from Japanese Phase III clinical trial of a bisphosphonate antiresorptive agent, ibandronate sodium hydrate oral agent, which is currently co-developed by Chugai and Taisho in Japan for the anticipated indication of osteoporosis. The MOVEST study, a randomized, multi center, double-blind, parallel group, controlled study, was conducted in approximately 400 patients (over 55 years of age) with osteoporosis to assess efficacy and safety of ibandronate oral formulation 100mg against ibandronate sodium hydrate injection [brand name: Bonviva IV Injection 1 mg Syringe (ibandronate injection)]. The increase in bone mineral density (BMD) of the lumbar spine (L2-L4) (percentage of relative change from baseline) at twelve month, the study's primary endpoint, was 5.22% for ibandronate oral formulation, and 5.34% [ 95% CI: 4.78% - 5.90% ] for ibandronate injection, respectively. The difference between the rate of change for ibandronate injection group of ibandronate oral formulation group (least squeares meane) was -0.23. It met the protocol criteria, a non-inferiority of ibandronate oral formulation to ibandronate injection has been demonstrated. The secondary endpoints of BMD gains in femur and inhibition on bone metabolic markers also showed similar effects between the two groups. No new safety signals were observed in the study. The safety profile was consistent with the previous overseas study results, and well tolerability of ibandronate oral formulation in osteoporotic patients was observed. Chugai filed a new drug application to the Ministry of Health, Labour and Welfare in February 2015, based on above and other data. Chugai and Taisho have been co-developing ibandronate oral formulation and Bonviva IV Injection in Japan as new treatment options for osteoporosis that improve adherence and offer patients wider choice of administration routes in Japan. Chugai and Taisho Toyama Pharmaceutical Co., Ltd. have been co-marketing Bonviva IV Injection, developed ahead of ibandronate oral formulation, since August, 2013 after Chugai obtained approval for osteoporosis indication in June, 2013. Following Bonviva IV Injection, Chugai and Taisho are determined to make efforts to obtain early approval of ibandronate oral formulation, a monthly oral agent and supply to patients and healthcare professionals.
Vernalis plc Enters into Research Collaboration with Taisho Pharmaceutical
Apr 7 15
Vernalis plc announced that it has entered into a drug discovery collaboration with Taisho Pharmaceutical Co., Ltd., utilizing Vernalis' fragment and structure-based drug discovery platform against an undisclosed target for the development of potential antibiotic agents.
Taisho Announces Encouraging Results from Two Phase III Diabetes Trials
Dec 9 13
Taisho Pharmaceutical Co., Ltd. has announced results from Phase III long-term administration clinical trials of the SGLT2 inhibitor luseogliflozin hydrate. The results were presented for the two Phase III clinical trials conducted in respect of Japanese Type 2 diabetes patients who cannot adequately control their blood glucose levels with the existing oral hypoglycemic agents. The clinical trials comprised Study-1, a long-term administration clinical trial in combined use with sulfonylurea glimepiride, and Study-2, a long-term administration clinical trial in combined use with 5 types of existing oral hypoglycemic agents. Study-1 targeted 221 Japanese Type 2 diabetes patients who cannot adequately control their blood glucose levels with sulfonylurea glimepiride. They were orally administered 2.5 mg of luseogliflozin or a placebo once daily for 24 weeks in a double blind trial. The results showed that the luseogliflozin significantly lowered the hemoglobin A1c (HbA1c), the study's primary endpoint.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|